## **ILLUMINA INC.**

ISIN: US4523271090 WKN: 452327109 Asset Class: Stock



## **Company Profile**

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

| Financial figures, Fiscal year: from 01.01. to 31.12. |                                    |               |                                    |                        |   |                |
|---|------------------------------------|---------------|------------------------------------|------------------------|---|----------------|
| Financial figures                                     | 2023 Assets Liabilities and equity |               | 2022 Assets Liabilities and equity |                        | <b>2021</b> Assets Liabilities and equity |                |
| Current assets  | 2,609,000,000                      |               | 3,561,000,000                      | Liabilities and equity | 2,713,000,000                             |                |
| Common stock capital                                  |                                    | 2,000,000     |                                    | 2,000,000              |   | 2,000,000      |
| Fixed assets  | 7,502,000,000                      |               | 8,691,000,000                      |                        | 12,504,000,000                            |                |
| Equity capital of a company                           |                                    | 5,745,000,000 |                                    | 6,599,000,000          |   | 10,740,000,000 |
| Cash and cash equivalents                             | 1,048,000,000                      |               | 2,011,000,000                      |                        | 1,232,000,000                             |                |
| Accrued liabilities                                   |                                    | 0             |                                    | 0                      |   | 0              |
| Other assets  | -                                  |               | -                                  |                        | -   |                |
| Current liabilities                                   |                                    | 1,570,000,000 |                                    | 2,773,000,000          |   | 1,093,000,000  |
| Prepayments and accrued income                        | -                                  |               | -                                  |                        | -   |                |
| Non-current liabilities                               |                                    | 2,796,000,000 |                                    | 2,880,000,000          |   | 3,384,000,000  |
| Diff  |                                    |               |                                    |                        |   |                |

| Non-current liabilities |                | 2,796,000,000  |                | 2,880,000,000  |                | 3,384,000,000  |
|-------------------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Different income        |                | -              |                | -              |                | -              |
| Other liabilities       |                | 620,000,000    |                | 649,000,000    |                | 915,000,000    |
| Total assets            | 10,111,000,000 | 10,111,000,000 | 12,252,000,000 | 12,252,000,000 | 15,217,000,000 | 15,217,000,000 |
|                         |                |                |                |                |                |                |
| Balance notes           |                |                |                |                |                |                |
|                         |                |                |                | 2023           | 2022           | 2021           |
| Accounting standard     |                |                | I              | US-GAAP        | US-GAAP        | US-GAAP        |
| Employees               |                |                |                | 12,010         | 11,500         | 9,800          |
| Equity ratio            |                |                |                | 56.82%         | 53.86%         | 70.58%         |
| Debt-equity ratio       |                |                |                | 76.00%         | 85.66%         | 41.69%         |
| Others                  |                |                |                |                |                |                |
|                         |                |                |                | 2023           | 2022           | 2021           |
|                         |                |                |                |                |                | 13.80%         |

## **ILLUMINA INC.**

ISIN: US4523271090 WKN: 452327109 Asset Class: Stock

| Income statement   |                |                |               |
|--|----------------|----------------|---------------|
|  | 2023           | 2022           | 2021          |
| Turnover   | 4,504,000,000  | 4,584,000,000  | 4,526,000,000 |
| Net income   | -1,161,000,000 | -4,404,000,000 | 762,000,000   |
| EBIT   | -1,021,689,000 | -4,020,690,500 | 879,322,500   |
| Operating income before taxes                                | -1,117,000,000 | -4,336,000,000 | 884,000,000   |
| Cash Flow  | 477,000,000    | 392,000,000    | 545,000,000   |
| Net interest income  | -19,000,000    | -15,000,000    | -61,000,000   |
| Research and development expenses                            | 1,330,000,000  | 1,321,000,000  | 1,185,000,000 |
| Income taxes   | 44,000,000     | 68,000,000     | 122,000,000   |
| Result from investments in subsidaries, associates and other | -              | -              | -             |
| Revenues per employee  | 348,957        | 370,905        | 429,739       |

## **Board of Directors**

| Members of Management Board |                                |  |
|-----------------------------|--------------------------------|--|
|                             |                                |  |
| Stephen MacMillan           | Chairman of Board of Directors |  |
| Frances Arnold              | Member of Board of Directors   |  |
| Gary Guthart                | Member of Board of Directors   |  |
| Robert Epstein              | Member of Board of Directors   |  |
| Scott Gottlieb              | Member of Board of Directors   |  |
| Andrew Teno                 | Member of Board of Directors   |  |
| Caroline Dorsa              | Member of Board of Directors   |  |
| Philip Schiller             | Member of Board of Directors   |  |
| Scott Ullem                 | Member of Board of Directors   |  |
| Susan Siegel                | Member of Board of Directors   |  |
| Jacob Thaysen               | Chairman of Managing Board     |  |
| Carissa Rollins             | Member of Executive Committee  |  |
| Joydeep Goswami             | Member of Executive Committee  |  |
| Kathryne Reeves             | Member of Executive Committee  |  |
| Steve Barnard               | Member of Executive Committee  |  |